The efficacy and safety of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis based on randomized controlled trials
BackgroundCabazitaxel (CAB) has been approved for the treatment of patients with progressed metastatic castration-resistant prostate cancer (mCRPC) after receiving docetaxel. To assess the efficacy and safety of CAB in mCRPC patients through systematic review and network meta-analysis.MethodsRandomi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1586650/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!